Effect of Facilitated Tucking on Procedural Pain During Heel Prick in Late Preterm Neonates: A Quasi-Experimental Study.

Clin TerJan 1, 2026
Clinical ResearchPediatrics

Divya Basavajyothi, Sowmini Padmanabh Kamath, Prasanna Mithra

✦ AI-curated · Sources linked

In 30 seconds

This quasi-experimental study assessed facilitated tucking during heel prick in 100 late preterm neonates (34 to < 37 weeks) at a tertiary care hospital. Neonates were assigned by alternate allocation to facilitated tucking or routine care, with pain measured using the PIPP-R score 30 seconds after the procedure. Median scores were lower with facilitated tucking than routine care (4.00 vs. 9.00, p < 0.001). The facilitated-tucking group also had a smaller heart-rate rise and less oxygen-saturation reduction, suggesting better physiological stability.

Key findings

  • Median PIPP-R pain scores were 4.00 with facilitated tucking and 9.00 with routine care (p < 0.001).
  • Facilitated tucking was associated with a smaller post-procedure rise in heart rate.
  • Oxygen saturation fell less after heel prick in neonates receiving facilitated tucking.

Why it matters

Heel pricks are common painful procedures in preterm neonates, and pain may affect physiological stability and neurodevelopment. These findings suggest that facilitated tucking may reduce measured pain and physiological disturbance during the procedure. The results add evidence for a non-pharmacological approach, while the study design means they should be interpreted as an association rather than definitive proof of benefit.

What to keep in mind

Alternate allocation was used rather than randomisation, and the authors state that randomized studies are needed to confirm the findings.

Source

Published in Clin Ter. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.